Pathway Genomics Corporation Raises Over $40 Million In Series E Financing

SAN DIEGO, CA – January 5, 2016 – Pathway Genomics Corporation, a global precision medicine company with mobile health solutions, today announced it has successfully raised over $40 million in a Series E financing. This brings the total investment into Pathway Genomics to over $130 million. Investors in this round of funding include IBM Watson, Pathway’s partner in the development of a mobile health application using artificial intelligence to provide personalized health and wellness guidance.  

Pathway Genomics Announces Definitive Settlement With United States

Pathway Genomics has reached a settlement with the United States Department of Justice. Pathway admits no wrongdoing as part of the settlement and is neither an admission of liability or wrongdoing by the Company, nor a concession by the United States that its claims are not well founded.

Pathway has fully cooperated with the inquiry and was not required to enter into a corporate integrity agreement. We now consider this matter closed. By resolving this issue we can stay focused on our growing business and avoid the time and expense of a potentially lengthy litigation process.

Although Pathway may debate some of the merits of the DOJ's allegations, we recognize and respect the government's responsibility to regulate industry practices. We continue to offer our full array of advanced genetic tests that empowers physicians and patients with accurate and actionable information that allows them to live better and healthier lives.

Media contact:

PR@pathway.com

Pathway Genomics’ Response to FDA Letter on CancerIntercept™ Detect

Pathway Genomics greatly respects and shares the FDA’s concerns about patient safety. We have received a letter from FDA, dated September 21, 2015, requesting certain information regarding the Pathway Genomics CancerIntercept™ Detect testing service.  We are carefully considering the concerns of the FDA as stated in their letter, and we will be responding to that letter.  We assure that there is physician involvement in the ordering, review and follow-up of CancerIntercept™ testing.  We believe that CancerIntercept™ Detect is a  laboratory developed test and, as a CLIA and CAP certified clinical laboratory, we are offering it as such.  While Pathway Genomics is involved in educating and marketing the tests to physicians and consumers, we do not believe this is a direct-to-consumer model. We believe we have performed appropriate validation of the test as a laboratory developed test, and we are in the process of performing additional studies.

Former Administrator of the U.S. Small Business Administration Hector Barreto Joins Pathway Genomics’ Strategic Advisory Board

Former Administrator of the U.S. Small Business Administration Hector Barreto Joins Pathway Genomics’ Strategic Advisory Board

Hector_Barreto_258x305
San Diego, CA – August 18, 2015Pathway Genomics, a global precision medical diagnostics company with mobile health applications designed to empower physicians and their patients to take control of their health and wellness, has announced today that Hector Barreto, the 21st Administrator of the U.S. Small Business Administration, has joined the Company’s Strategic Advisory Board. Click to Tweet  

Former United States Secretary of Commerce Barbara Franklin Joins Pathway Genomics’ Board of Directors

Barbara Franklin
Former United States Secretary of Commerce Barbara Franklin Joins Pathway Genomics’ Board of Directors   San Diego, CA – June 16, 2015Pathway Genomics Corporation, a global precision medicine company with mobile health solutions for clinical laboratory testing to empower physicians and their patients to take control of their health and wellness, announced today that the 29th U.S. Secretary of Commerce, The Honorable Barbara Franklin is joining the company’s Board of Directors. Click to Tweet  

Pathway Genomics Launches First Hispanic Targeted Screening Panel for BRCA1/2-Related Hereditary Cancers

BRCATrue™ Hispanic (8-Site)
San Diego, CA – June 2, 2015 – Pathway Genomics Corporation, a data-driven global healthcare company and precision medicine clinical laboratory, announced today the launch of BRCATrue™ Hispanic (8-Site), a site-specific genetic testing panel consisting of 8 recurrent BRCA1 and BRCA2 pathogenic variants found in individuals of Mexican and Hispanic descent.  

Former Chairman of the Joint Chiefs of Staff U.S. General Peter Pace joins Pathway Genomics Board of Directors

U.S. General Peter Pace
San Diego, CA – May 19, 2015 - Pathway Genomics Corporation, a data-driven global healthcare company and precision medicine clinical laboratory announced today that the sixteenth Chairman of the Joint Chiefs of Staff, retired U.S. Marine General Peter Pace is joining the company’s Board of Directors.  

Jim Plante, Founder and CEO of Pathway Genomics, Appointed by US Secretary of Commerce and US Trade Secretary to Industry Trade Advisory Committee (ITAC)

Jim Plante - Pathway Genomics
SAN DIEGO, CA / Washington DC May 14, 2015 – Pathway Genomics Corporation, a data-driven global healthcare company and global clinical laboratory, today announced that Founder and CEO Jim Plante has been appointed by the U.S. Secretary of Commerce, Penny Pritzker, and U.S. Trade Representative (USTR), Ambassador Michael Froman to the Industry Trade Advisory Committee on Chemicals, Pharmaceuticals, Health and Science Products (ITAC 3).  

Pathway Genomics Launches Updated Next Generation Sequencing Tests for Colorectal Cancer

SAN DIEGO, Mar 26, 2015 (BUSINESS WIRE) -- Pathway Genomics Corporation, a forward-thinking big data healthcare company and global precision medicine clinical laboratory, announced it has launched ColoTrue™, a comprehensive panel that combines next-generation sequencing with deletion/duplication analysis to detect pathogenic variants in 15 high-risk colorectal cancer susceptibility genes. Pathway has also launched a smaller panel, LynchSyndromeTrue™, which tests for Lynch syndrome, the most common form of hereditary colon cancer.  

Pathway Genomics Appoints Former Cedars-Sinai Chair of Medicine Glenn D. Braunstein, M.D., as Chief Medical Officer

braunstein
San Diego, CA – March 11, 2015 – Pathway Genomics Corporation, a forward-thinking big data healthcare company and global precision medicine clinical laboratory, has announced that endocrinologist Dr. Glenn D. Braunstein is the company’s new Chief Medical Officer. Dr. Braunstein takes on the role after serving on Pathway Genomics’ Strategic Advisory Board. With a special interest in pharmacogenomics, Dr. Braunstein’s first priority will be Pathway Genomics’ pharmacogenomic testing menu.